Adverse events · participants with chronic prostatitis/chronic pelvic pain syndrome
1 finding from 1 review
Sexual dysfunction ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression and anxiety ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion with complete resolution of a target tophus · participants with tophi in gout
Lesinurad 200 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Lesinurad 400 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).
1 finding from 1 review
Pain reduction ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Tophus regression · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Allopurinol 100‐300 mg daily showed no clear difference in withdrawal due to adverse effects compared with febuxostat 80 mg daily (moderate certainty).
1 finding from 1 review
Serious adverse effects · people with chronic gout
Allopurinol 100‐300 mg daily showed no clear difference in serious adverse effects compared with febuxostat 80 mg daily (moderate certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Allopurinol 100‐300 mg daily showed no clear difference in acute gout attacks compared with febuxostat 80 mg daily (low certainty).
1 finding from 1 review
Proportion achieving target serum urate · people with chronic gout
Allopurinol 100‐300 mg daily may leads to lower proportion achieving target serum urate compared with febuxostat 80 mg daily (low certainty).
1 finding from 1 review
Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Allopurinol mouthwash led to higher improvement in mucositis compared with placebo; GRADE not reported.
1 finding from 1 review
Mucositis eradicated · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Allopurinol mouthwash led to higher mucositis eradicated compared with placebo; GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Allopurinol mouthwash led to lower time to heal mucositis (days) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Allopurinol mouthrinse led to lower oral mucositis (moderate to severe) compared with placebo/no treatment; GRADE not reported.
1 finding from 1 review
RR 0.66 [0.5, 0.86]
2 studies
GRADE not reported
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Allopurinol mouthrinse showed no clear difference in oral mucositis (any severity) compared with placebo/no treatment; GRADE not reported.
1 finding from 1 review
RR 0.77 [0.5, 1.19]
4 studies
GRADE not reported
Tumour response · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
All‐cause mortality at last · people with liver metastases
Summary of Findings Table ‐ Electrocoagulation in combination with… may leads to lower all‐cause mortality at last compared with control (vehicle solution of allopurinol by mouth) (low certainty).
1 finding from 1 review